Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

Wang, Xuanting; Sacramento, Carolina Q.; Jockusch, Steffen; Chaves, Otávio Augusto; Tao, Chuanjuan; Rodrigues, Natalia Fintelman; Chien, Minchen; Temerozo, Jairo Ramos; Xaioxu, Li; Kumar, Shiv; Xie, Wei; Patel, Dinshaw J.; Meyer, Cindy; Garzia, Aitor; Tuschi, Thomas; Bozza, Patrícia Torres; Russo, James J.; Souza, Thiago Moreno L.; Ju, Jingyue.
No convencional en Inglés | ARCA | ID: arc-48718

Documentos relacionados

  1. Host Recovery from Respiratory Viral Infection.
  2. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  3. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
  4. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation.
  5. Mechanisms of SARS-CoV-2 entry into cells.
  6. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak.
  7. COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
  8. Combination therapies for COVID-19: An overview of the clinical trials landscape.
  9. Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.
  10. Therapeutic use of calpeptin in COVID-19 infection.